the design aglow posing guide for family portrait photography
LINK 1 ENTER SITE >>> Download PDF
LINK 2 ENTER SITE >>> Download PDF
File Name:the design aglow posing guide for family portrait photography.pdf
Size: 3367 KB
Type: PDF, ePub, eBook
Category: Book
Uploaded: 5 May 2019, 16:45 PM
Rating: 4.6/5 from 796 votes.
Status: AVAILABLE
Last checked: 6 Minutes ago!
In order to read or download the design aglow posing guide for family portrait photography ebook, you need to create a FREE account.
eBook includes PDF, ePub and Kindle version
✔ Register a free 1 month Trial Account.
✔ Download as many books as you like (Personal use)
✔ Cancel the membership at any time if not satisfied.
✔ Join Over 80000 Happy Readers
the design aglow posing guide for family portrait photographyOur payment security system encrypts your information during transmission. We don’t share your credit card details with third-party sellers, and we don’t sell your information to others. Please try again.Please try again.Please try again. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required. Register a free business account He lives in Wynnewood, PA. David A. Horowitz, MD, is the Associate Director of Program Development at the Department of Health and Disease Management, University of Pennsylvania Health System, and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania. He lives in Ardmore, PA.Full content visible, double tap to read brief content. Videos Help others learn more about this product by uploading a video. Upload video To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. It also analyzes reviews to verify trustworthiness. Please try again later. M. Thakery 4.0 out of 5 stars I have found all of the AmercanCollege books to be accurate and timely enough to have confidence whengiving them out that I am providing a good resource. If I did not, Icertainly would not recommend them here. Aside from this one complaint, Ihave found this to be an EXCELLENT book and would recommend it foranyone with chronic headaches! To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. It also analyzes reviews to verify trustworthiness. See All Buying Options Add to Wish List Disabling it will result in some disabled or missing features. You can still see all customer reviews for the product. Please try again later. From the United StatesI have found all of the AmercanCollege books to be accurate and timely enough to have confidence whengiving them out that I am providing a good resource.http://elitedentallasvegas.com/userfiles/dell-pp36x-service-manual.xml
- Tags:
- the design aglow posing guide for family portrait photography, the design aglow posing guide for family portrait photography backdrops, the design aglow posing guide for family portrait photography for beginners, the design aglow posing guide for family portrait photography techniques, the design aglow posing guide for family portrait photography gallery, the design aglow posing guide for family portrait photography software, the design aglow posing guide for family portrait photography photos, the design aglow posing guide for family portrait photography portraits, the design aglow posing guide for family portrait photography images.
Aside from this one complaint, Ihave found this to be an EXCELLENT book and would recommend it foranyone with chronic headaches!Please try again later. Groups Discussions Quotes Ask the Author Fully veiled by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), each book covers a single topic or disease, providing clear and concise information in a highly accessible format. All are completely up-to-date, with the latest advances i Fully veiled by the American College of Physicians-American Society of Internal Medicine (ACP-ASIM), each book covers a single topic or disease, providing clear and concise information in a highly accessible format. All are completely up-to-date, with the latest advances in diagnosis, treatment, self-help, and preventive measures, and are illustrated throughout with over 75 photographs, diagrams, and charts. The series is being launched with 14 titles; future topics will include a wide range of medical and general health topics ranging from depression and arthritis to menopause and nutrition. To see what your friends thought of this book,This book is not yet featured on Listopia.There is a lot of examples in real life on the book that are talking about their symptoms and treatments about the headache and migraines and how they develop with it. This book is interesting and it advice on understanding migraines and other headache. This book includes the causes and triggers of migraine, how to live with migraines treatment,both conventiona There is a lot of examples in real life on the book that are talking about their symptoms and treatments about the headache and migraines and how they develop with it. This book includes the causes and triggers of migraine, how to live with migraines treatment,both conventional and complementary. Also help you to know other types of headache. It's a good self help,and lifestyle. There are no discussion topics on this book yet.http://www.holidayhomecare.co.nz/userfiles/dell-pp29l-service-manual-pdf.xml Guaranteed Service International Shipping Know More Free Home Delivery above ?499 Check Delivery We have a problem Your form could not be submitted, try again later. Covers symptoms, tests,Includes causes of migraines,All rights reserved. Please enable Javascript on your browser We don't support without Javascript enabled in your browser. Please enable Javascript in your browser settings and reload this page. Please upgrade your browser to improve your experience. Please upgrade your browser to allow continued use of ACP websites. Join a distinguished group of over 31,000 internists and leaders who already share this honor. Ideal for reviewing knowledge. Get answers now. Join a distinguished group of over 31,000 internists and leaders who already share this honor. Ideal for reviewing knowledge. Get answers now. Diagnosis and Initial Management Migraine is a primary headache disorder with a wide variety of manifestations. Recurrent acute attacks may not have the same characteristics in all patients or even in the same patient. Criteria for the diagnosis of migraine have been developed by the International Headache Society. However, physicians need to be aware that a patient can have more than one headache disorder (e.g., migraine and episodic tension-type headaches). Patient Education and Involvement Recommendation. The patient should be educated about the control of acute migraine attacks and preventive treatment. The patient should be involved in formulating a management plan. Regular reevaluation of therapy is important. A discussion of the benefits and adverse effects of therapeutic options can help the patient establish realistic expectations. Together, the physician and patient should decide how acute attacks are to be treated and whether the patient would benefit from preventive medication. Patient input is crucial to treatment selection and evaluation. Tracking progress with a daily flow sheet can be helpful in assessing treatment.https://labroclub.ru/blog/boss-gt-3-manual The patient's headache diary should include the severity, frequency, and duration of migraine attacks; the degree of disability resulting from the attacks; the response to treatment; and adverse effects from medication. The patient also should be encouraged to identify factors or situations that trigger migraines (e.g., alcohol, caffeine, foods containing tyramine or nitrates, stress, fatigue, perfumes, fumes, glare, flickering lights). Management of Acute Attacks Management of acute migraine attacks needs to be individualized. Factors to consider include associated symptoms (e.g., nausea, vomiting), the frequency and severity of the attacks, and the degree of disability caused by the attacks. Comorbid conditions (e.g., uncontrolled hypertension, heart disease, pregnancy) and previous responses to specific medications may limit treatment options. To guard against medication-overuse headaches, experts suggest limiting the use of acute treatment to no more than twice a week. Preventive migraine therapy should be considered if medication overuse is suspected or considered to be a risk. Consideration should be given to the possibility of rebound headaches, which are associated with the withdrawal of analgesic drugs or abortive migraine medications. Although universal agreement is lacking, it is generally thought that rebound headaches can be caused by opiates, triptans, ergotamine, and analgesic medications that contain caffeine, isometheptene, or butalbital. The physician may need to consider the patient's use of a rescue medicine (e.g., an opioid, a compound that contains butalbital) at home when other treatments for severe migraine attacks are not successful. Appropriate situations for use should be addressed. Recommendation. In most patients with migraine, non-steroidal anti-inflammatory drugs (NSAIDs) are first-line treatment.http://pepsy-massage-sexy.com/images/95-honda-civic-service-manual-pdf.pdf Evidence for efficacy is most consistent for these agents: aspirin, ibuprofen, naproxen sodium, tolfenamic acid (not currently available in the United States), and the acetaminophen-aspirin-caffeine combination. Acetaminophen alone is ineffective. Triptans should not be used in a patient who has uncontrolled hypertension or basilar or hemiplegic migraine or who is at risk for heart disease. Evidence for efficacy and safety is good for intranasally administered DHE. There also is good evidence for the efficacy of butorphanol nasal spray. Treatment with opioids may be considered if other medications cannot be used and if the risk of abuse has been addressed and sedation is not a concern. Recommendation. A nonoral route of administration should be selected when nausea or vomiting present early as significant components of migraine attacks. Nausea should be treated with an antiemetic drug. Recommendation. The patient with migraine should be evaluated for the use of preventive treatment. Commonly accepted indications for migraine prevention are as follows: two or more migraine attacks per month, with the attacks producing disability for three or more days per month; use of rescue medication more than twice a week; failure of acute treatments or contraindications for such treatments; or the presence of uncommon migraine conditions (e.g., prolonged aura, migrainous infarction, hemiplegic migraine). Additional factors that need to be considered include the patient's preference, adverse events with treatments for acute migraine attacks, and how much treatment costs for acute attacks and migraine prevention. Recommendation. First-line agents for the prevention of migraines are as follows: propranolol, 80 to 240 mg per day; timolol, 20 to 30 mg per day; amitriptyline, 30 to 150 mg per day; divalproex sodium, 500 to 1,500 mg per day; and sodium valproate, 800 to 1,500 mg per day. Some other drugs have been shown to be efficacious, but data on associated adverse events are limited. These agents include methysergide and a number of agents that currently are not available in the United States, including flunarizine, lisuride, pizotifen, and time-released DHE. There is good evidence for the efficacy of propranolol and timolol. Common adverse effects of beta blockers, including dizziness, nausea, fatigue, depression, and insomnia, appear to be tolerated fairly well. Recommended medications based on at least two double-blind, placebo-controlled trials and clinical impression of effect: oral acetaminophen-aspirin-caffeine; oral aspirin; intranasal butorphanol; SC, IM, IV, or intranasal DHE; IV DHE plus an antiemetic; oral ibuprofen; oral naproxen sodium; oral naratriptan; IV prochlorperazine; oral rizatriptan; SC, intranasal, or oral sumatriptan; oral zolmitriptan Use NSAIDs as first-line therapy. Recommended agents: intranasal DHE, oral naratriptan, SC or oral sumatriptan, oral rizatriptan, oral zolmitriptan Select a nonoral route of administration for patients whose migraines present early with nausea or vomiting as a significant component of the symptom complex. Select a nonoral route of administration for patients whose migraines present early with nausea or vomiting as a significant component of the symptom complex. Treat nausea with an antiemetic. Educate patients with migraine about their condition and its treatment, and encourage them to participate in their own management. Preventive Medication use: initiate treatment with lowest effective dose; give each treatment an adequate trial; avoid interfering medications; use a long-acting formulation to improve adherence. Patients with migraine should be evaluated for use of preventive therapy. Generally accepted indications for migraine prevention include (1) two or more attacks per month that produce disability that lasts three or more days per month, (2) contraindication to, or failure of, acute treatments, (3) use of abortive medication more than twice per week, or (4) the presence of uncommon migraine conditions, including hemiplegic migraine, migraine with prolonged aura, or migrainous infarction. Therapy should be reevaluated on a regular basis. Evaluation: monitor patients' headaches by having them keep headache diaries; reevaluate therapy. Encourage patients to be actively involved in their management by tracking their own progress through daily flow sheets, for example. Diaries should measure attack frequency, severity, duration, disability, response to type of treatment, and adverse effects of medication. Comorbid conditions: once a comorbid condition is identified, select a pharmacologic agent that will treat both disorders; establish that the coexisting condition is not a contraindication to the selected migraine therapies and that the therapy will not exacerbate the migraine. Adapted with permission from Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. One comparative trial suggested that propranolol is superior in the patient with migraine alone, but that amitriptyline is more effective in the patient with mixed migraine and tension-type headache. Tricyclic antidepressants, including amitriptyline, can cause weight gain, drowsiness, and anticholinergic symptoms. Evidence for efficacy is good for divalproex sodium and sodium valproate. These agents may be particularly effective in the patient who has prolonged or atypical migraine aura. Adverse effects can include hair loss, tremor, weight gain, and teratogenic effects (e.g., neural tube defects). Once a drug for migraine prevention has been chosen, treatment should be initiated with a low dose. The dose should be increased slowly until benefits are achieved without adverse effects or are limited by adverse events. An adequate trial of the drug is important because clinical benefits may not become apparent for two to three months. After a period of stability, consideration can be given to tapering or discontinuing the drug. Read the full article. Get immediate access, anytime, anywhere. Choose a single article, issue, or full-access subscription. Earn up to 6 CME credits per issue.A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact Get Permissions Sign up for the free AFP email table of contents. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers. References 1. Ann Intern Med. 1978;88:162-7 Link Google Scholar 4. Evidence-based guidelines for migraine headache: neuroimaging in patients with nonacute headache. U.S. Headache Consortium; 2000. Accessed at www.aan.com on 15 February 2017. Google Scholar 6. Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.The transfer of drugs and therapeutics into human breast milk: an update on selected topics.Funding Source: American College of Physicians. Disclosures: Dr. MacGregor, ACP Contributing Author, reports personal fees from Menarini outside the submitted work. With the assistance of additional physician writers, the editors of Annals of Internal Medicine develop In the Clinic using MKSAP and other resources of the American College of Physicians. In the Clinic does not necessarily represent official ACP clinical policy. For ACP clinical guidelines, please go to. Comments are moderated. What is the problem and what is known about it so far. Migraines are headaches related to changes in chemicals and blood vessels in the brain. Doctors use many types of drugs to treat or prevent migraines, but it is unclear which drugs work best.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine. Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Comments are moderated. Which of the following findings in patients with botulism best differentiates it from GBS? Headache is one of the most common reasons patients seek medical attention. If the patient has had previous or recurrent headaches, the previous diagnosis (if any) needs to be identified, and whether the current headache is similar or different needs to be determined. For recurrent headaches, the following are noted: Patients may complete the questionnaire before their visit and bring the results with them. General appearance (eg, whether restless or calm in a dark room) is noted. A general examination, with a focus on the head and neck, and a full neurologic examination are done. The ipsilateral temporal artery is palpated, and both temporomandibular joints are palpated for tenderness and crepitance while the patient opens and closes the jaw. Pupillary size and light responses, extraocular movements, and visual fields are assessed. The fundi are checked for spontaneous retinal venous pulsations and papilledema. If patients have vision-related symptoms or eye abnormalities, visual acuity is measured. If the conjunctiva is red, the anterior chamber and cornea are examined with a slit lamp if possible, and intraocular pressure is measured. The oropharynx is inspected for swellings, and the teeth are percussed for tenderness. The cervical spine is palpated for tenderness. Headaches that have recurred since childhood or young adulthood suggest a primary headache disorder. If headache type or pattern clearly changes in patients with a known primary headache disorder, secondary headache should be considered. A combination of symptoms and signs is more characteristic (see table Some Characteristics of Headache Disorders by Cause ). However, some serious disorders may require urgent or immediate testing. Some patients require tests as soon as possible. Patients with a thunderclap headache require CSF analysis even if CT and examination findings are normal as long as lumbar puncture is not contraindicated by imaging results. CSF analysis is also indicated if patients with headache are immunosuppressed. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. The Merck Manual was first published in 1899 as a service to the community. The legacy of this great resource continues as the Merck Manual in the US and Canada and the MSD Manual outside of North America. Learn more about our commitment to Global Medical Knowledge. Download Background Document August 2013 Download Background Document Download Resource List National Opioid Use Guideline Group (NOUGG), endorsed by the College of Physicians and Surgeons of Alberta (CPSA); 2010. Available at: Edmonton, AB, Canada T5J 3N4. Most content still can be accessed, but transactions such as ACEP20 registration, membership updates, members-only content or CME purchases will be temporarily unavailable. We apologize for the inconvenience and our Member Care team will be available to help you until 10 pm CDT at (844) 381-0911. In instances in which consensus recommendations are made, “consensus” is placed in parentheses at the end of the recommendation. Factors such as heterogeneity of results, uncertainty about effect magnitude, and publication bias, among others, might lead to a downgrading of recommendations. An estimated 6 of men and 15 to 17 of women in the United States have migraine, but only 3 to 5 of them receive preventive therapy. 2 Furthermore, migraine is often undiagnosed. 3 About half of migraine patients stop seeking care for their headaches, partly because they are dissatisfied with therapy. Indeed, public surveys indicate that headache sufferer s are among the most dissatisfied patients. 4 In addition to being dissatisfied with their care, many migraineurs report significant disability and an impaired quality of life. Migraine is heterogeneous (among sufferers and between attacks) in frequency, d uration, and disability. Some migraineurs have fewer than one attack a month while others have one or more attacks a week. 5 Some are quite disabled by their headaches, while others are not. Therefore, it is appropriate to stratify the care of the migraine population by headache frequency, severity, and level of disability, and to consider prevention for those patients whose migraine has a substantial impact on their lives. 6 With this background, the objective of the US Headache Consortium is to develop sci entifically sound, clinically relevant practice guidelines for headache in the primary care setting. These headache Guidelines review the evidence published in the literature and propose diagnostic and therapeutic recommendations to improve the care and sa tisfaction of migraine patients. This specific document focuses on the prevention of migraine attacks. Additional recommendations for Goals of Treatment for Prevention of Migraine The goals of migraine preventive therapy are to: (1) reduce attack frequency, severity, and d uration; (2) improve responsiveness to treatment of acute attacks; and (3) improve function and reduce disability. Aims of the Guideline Consensus in this context means unanimous agreement unless explicitly stated otherwise. B. Summary of the Evidence The AHCPR Technical Review 12 reviewed 283 controlled trials of pharmacological agents used to prevent migraine. The main findings of the AHCPR Technical Review are summarized below. The various classes of pharmacological agents are reviewed in alphabetical order. The AHCPR Technical Review included controlled trials indexed in MEDLINE January 1966 through December 1996. Several additional randomized controlled trials for migraine prevention were published after this date and are individually reviewed. Newly published materials not included in the evidence analysis are incorporated into treatment re commendations as appropriate, and these recommendations are based on consensus. It is based on an assessment of current scientific and clinical information. It is not intended to include all possib le proper methods of care for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. These For example, while most modern clinical trials of acute migraine treatment rely on uniform endpoints with minor variations, endpoints in migrai ne prevention trials are more diverse. The AHCPR Technical Review relied on a headache index for effect - size analysis despite the fact that this is confounded by acute and rescue therapies. Other endpoints included headache frequency and headache intensity. Clinical trials completed after 1991 often used a reduction in the total number of headache attacks in a 28 - day period or the p roportion of patients with a greater than 50 reduction in headache frequency as endpoints. When they were used, effect - size analysis was based on these endpoints. (4) Most comparative trials of two or more active treatments did not include a placebo arm. The scientific rigor of these trials is weak, particularly in light of a potential placebo response (at least 20) and since improvement over baseline could be a reflection of the natural history of the illness during treatment. 16 - 18 organizations recognize that specific patient care decisions are the prerogative of the patient and the ph ysician caring for the patient, based on all of the circumstances involved. Alpha - 2 agonists The AHCPR Technical Review included 17 controlled trials of alp ha - 2 agonists for the prevention of migraine: 16 of clonidine, 19 - 34 and one of guanfacine. 30 The evidence from these trials suggests that alpha - 2 agonists are minimally, and not conclusively, efficacious. These and other symptoms were reported by a high proportion of patients, but were usually neither serious nor cause for withdrawal from the trials.No information was available on adverse events associated with guanfacine. The only placebo - controlled trial of carbamazepine suggested a significant benefit, but this trial was inadequatel y described in several important respects. 41 Another trial, comparing carbamazepine with clonidine and pindolol, suggested that carbamazepine had a weaker effect on headache frequency than either comparator treatment, though differences from clonidine were not statistically significant. 33 The anticonvulsant clonazepam (vs.The fourth trial found significantly higher rates of nausea, asthenia, somnolence, vomiting, tremor, and alopecia when patients used divalproex sodium. (Additional adverse events are detailed in Table 1.) A significantly higher percentage of patients reported adverse events with carbamazepine than with placebo or pindolol; there was no significant difference in this respect between carbamazepine and clonidine. Limited data were reported on adverse events associated with clonazepam and gabapentin. The most common adverse events reported in association with these tre atments were dizziness or giddiness, and drowsiness. Relatively high patient withdrawal rates due to adverse events were reported in some trials. 12 Timolol, 77,98,99 atenolol, 100 - 102 and nadolol 103 - 108 are also likely to be ben eficial based on comparisons with placebo or with propranolol.Nimodipine has been less thoroughly studied than flunarizine and had mixed results in placebo - controlled trials.Both active treatments were well - tolerated. 148 The trials reviewed in the AHCPR Technical Review provided little useful information on the risk of adverse events with these agents. The proportion of patients reporting adverse events vari ed considerably from trial to trial, even among trials reporting on the same pharmacological Symptoms reported with other calcium channel antagonists included dizziness, edema, flushing, and constipation. Placebo - co ntrolled trials of aspirin, 155,156 aspirin plus dipyridamole, 156,157 fenoprofen, 158,159 and indomethacin 163 were inconclusive. In a placebo - controlled, randomized, double - blind trial, nabumetone, an NSAID, was not found to be significantly different from p lacebo in reducing migraine frequency. 166 Comparisons of NSAIDs with the beta - blockers propranolol 165,167 and metoprolol 94 demonstrated no important differences.It was one of the first pharmacological agents to be used and studied for the prevention of migraine, but its usefuln ess is now limited by reports of retroperitoneal and retropleural fibrosis associated with long - term, mostly uninterrupted, administration. Similarly, two trials directly comparing methysergide and propranolol f ailed to demonstrate any statistically significant differences between these Methysergide was associated with a higher incidence of adverse events t han was placebo. Gastrointestinal complaints were most common and included nausea, vomiting, abdominal pain, and diarrhea. Also frequently reported were leg symptoms (restlessness or pain), dizziness, giddiness, drowsiness, lassitude, and paresthesia. The duration of the trials reviewed here was too short to detect the fibrotic complications sometimes observed with long - term use of methysergide.The trials were all relatively small, and they varied markedly in patient population, dosages used and clinical results.These three studies measured different endpoints. It does not address the general principles of care for migraine prevention, and it does not discuss which medication should be considered first. This fine - tuning process requires a consensus that incorporates levels of quality of the evidence, magnitude of the benefit of a particular medication, clinical impressions from prior experience, tolerability, and safety profile. D. General Principles of Management The following consensus - based (not evidence - based) principles of care will enhance the success of preventive treatment.